GSK
GlaxoSmithKline PLC
49.70$
+0.9%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +4.0% | +16.6% | +8.2% | +2.1% | +9.5% | -27.8% | +1.4% | +18.7% | +3.4% | +3.5% | +4.1% | |
| – | +20.9% | +4.9% | +11.3% | -1.0% | +15.8% | -33.2% | +3.0% | +17.0% | -10.4% | +5.6% | -0.3% | |
| – | -3.9% | +23.4% | +6.7% | +3.7% | +6.4% | -25.0% | +0.7% | +19.6% | +10.1% | +2.6% | +5.9% | |
| – | +3.2% | +1.9% | +23.4% | -13.0% | +17.3% | +4.9% | +4.7% | +9.3% | +13.4% | +2.9% | +17.6% | |
| – | +12.0% | +1.5% | +3.3% | +2.5% | +15.0% | -34.8% | -4.9% | +18.4% | +12.1% | +17.4% | -17.5% | |
| – | -60.7% | +237.0% | -1.5% | -4.2% | -1.1% | -30.0% | +16.6% | +9.5% | +12.6% | +21.9% | -16.4% | |
| – | +187.0% | -74.8% | +57.3% | +34.2% | +27.0% | -14.1% | -27.1% | +47.6% | +4.8% | -40.4% | +107.4% | |
| – | +8.7% | -2.8% | -0.3% | +1.3% | +22.6% | -2.2% | -12.1% | +9.1% | -9.4% | -15.2% | +4.5% | |
| – | +254.6% | -81.6% | +81.8% | +36.2% | +29.6% | -16.9% | -30.4% | +56.4% | +7.7% | -42.7% | +112.9% | |
| – | +1,472.3% | -59.3% | +54.6% | -44.4% | +26.4% | -93.0% | +23.9% | +751.8% | +6.9% | -30.4% | +111.4% | |
| – | +205.6% | -89.2% | +68.0% | +136.5% | +28.2% | +23.8% | -23.7% | +241.1% | -67.1% | -47.7% | +122.0% | |
| – | +150.1% | -65.6% | +39.6% | +18.9% | +25.4% | -12.5% | -19.6% | +32.6% | +5.6% | -26.6% | +56.0% |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.